WuXi buyout deal raises questions on scientists' pay scale

The average scientist on WuXi PharmaTech's Chinese payroll earns about $30,000 a year, roughly equivalent to 10 percent of what it costs to emply an American researcher with the same qualifications. Numbers like that make analysts salivate at the earnings potential of the publicly traded company, which has been renting out scientists to drug developers anxious to operate on a lean and mean R&D budget. WuXi recently moved to acquire the U.S. research and testing firm AppTec Laboratory Services, which may put some strain on the company's operating plan. I'd be willing to bet that scientists at AppTec--or anywhere else in the developed world, for that matter--aren't salivating over WuXi's pay scale.

- read the report in the Wall Street Journal

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.